Key result
DOACs match traditional anticoagulants for recurrent VTE in fragile patients with comparable or lower bleeding risk.
Why the study?
Do direct oral anticoagulants improve outcomes compared to traditional anticoagulants in fragile patients with venous thromboembolism?
Do direct oral anticoagulants improve outcomes compared to traditional anticoagulants in fragile patients with venous thromboembolism?
DOACs are effective and generally safe for VTE management in vulnerable populations like the elderly, cancer patients, and those with early-stage CKD, though caution remains for advanced CKD and dialysis.
Answers are grounded in this paper and cite their sources.
May support DOAC use in fragile VTE patients; leaves open dedicated trials for advanced CKD.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Park et al. (2024) conducted a review in Venous thromboembolism. Direct oral anticoagulants (DOACs) vs. Traditional anticoagulants (heparin, low-molecular-weight heparin, warfarin) was evaluated. Direct oral anticoagulants are as effective as traditional anticoagulants in preventing recurrent venous thromboembolism with comparable or lower bleeding risks in fragile patients with cancer, early-stage chronic kidney disease, and advanced age.
Synapse has enriched 10 related papers. Consider them for comparative context: